The Signal
Hims becomes a case study in concentrated investing just as the FDA reopens review of 12 peptides and warns that restrictions may push demand into a dangerous black market. The stream works through the bull and bear case with an open mind, then ends on Jensen Huang's argument that excluding China from US chips would surrender the computing market rather than secure it.
Key Takeaways
- 01
Crypto's chart exceeds its narrative
Prices look decent and low-quality tokens rally, but Threadguy finds the cultural and fundamental energy weak. Hyperliquid remains the notable exception.
- 02
Peptide policy can shift demand underground
The FDA plans expert review of 12 substances beginning in July. Restricting compounding without meeting demand could enlarge unsafe black markets.
- 03
Concentration forbids self-deception
In a two-stock portfolio, every thesis must be revisited from the skeptical side. The Hims analysis explicitly re-underwrites the business rather than defending an identity.
- 04
Hims owns distribution, not the molecule
Its strength is acquiring and retaining patients through a consumer brand. Its vulnerability is regulation, supplier dependence, and competition around products it does not exclusively control.
- 05
China is too large to concede
Jensen Huang argues that blocking US chips from China hands the market to domestic alternatives and weakens America's long-term position across the computing stack.
On the Record
“When you run a two stock portfolio as I do, there's no room for delusion.”
“Listen to the bear case with an open mind.”
“Conceding the entire market is not going to allow United States to win the technology race long-term.”
The Breakdown
A green chart with a weak story
Equities and crypto close reasonably well, but Threadguy distrusts a rally led by low-quality tokens. HYPE around $44 has clearer use; the rest feels like price without renewed conviction.
The FDA reopens the peptide file
Regulators remove 12 peptides from a restrictive category and send them to advisory meetings beginning in July for clinical, pharmaceutical, and safety review. The decision acknowledges evidence while warning that unregulated demand can migrate underground.
Sizing makes honesty mandatory
Threadguy reads an investor's Hims re-underwriting built around a two-stock portfolio. With half a book potentially exposed, there is no room to preserve a thesis for ego; every assumption must survive hostile review.
The Hims bull case
Hims has a recognizable consumer brand, digital acquisition engine, and ability to bundle care in stigmatized or inconvenient categories. Peptides could extend that distribution advantage into another high-demand market.
The Hims bear case
The company depends on regulation and access to treatments it did not invent. Enforcement, safety findings, branded-drug competition, or rising acquisition costs can weaken margins quickly, making the peptide opportunity inseparable from policy risk.
Jensen refuses to abandon China
The closing interview presses Huang on export restrictions. He argues that leaving the Chinese market does not freeze progress; it encourages replacement suppliers and forfeits the installed base. Competing there, in his view, is necessary to preserve US leadership in chips and computing.
Distilled from the episode transcript · Counterparty Recap Desk
![The $300,000,000 Crypto HACK... [Stream Recap]](https://i.ytimg.com/vi/vG0e6y-lDEw/hq720.jpg)
![The AI Bubble Just Got WORSE.. [Stream Recap]](https://i.ytimg.com/vi/zQYD8glu3cQ/hq720.jpg)
![The Stock Market Just Fooled Everyone... [Stream Recap]](https://i.ytimg.com/vi/BWpIVJef2Uk/hq720.jpg)